1
|
Silva MLS. Capitalizing glycomic changes for improved biomarker-based cancer diagnostics. EXPLORATION OF TARGETED ANTI-TUMOR THERAPY 2023; 4:366-395. [PMID: 37455827 PMCID: PMC10344901 DOI: 10.37349/etat.2023.00140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2022] [Accepted: 02/24/2023] [Indexed: 07/18/2023] Open
Abstract
Cancer serum biomarkers are valuable or even indispensable for cancer diagnostics and/or monitoring and, currently, many cancer serum markers are routinely used in the clinic. Most of those markers are glycoproteins, carrying cancer-specific glycan structures that can provide extra-information for cancer monitoring. Nonetheless, in the majority of cases, this differential feature is not exploited and the corresponding analytical assays detect only the protein amount, disregarding the analysis of the aberrant glycoform. Two exceptions to this trend are the biomarkers α-fetoprotein (AFP) and cancer antigen 19-9 (CA19-9), which are clinically monitored for their cancer-related glycan changes, and only the AFP assay includes quantification of both the protein amount and the altered glycoform. This narrative review demonstrates, through several examples, the advantages of the combined quantification of protein cancer biomarkers and the respective glycoform analysis, which enable to yield the maximum information and overcome the weaknesses of each individual analysis. This strategy allows to achieve higher sensitivity and specificity in the detection of cancer, enhancing the diagnostic power of biomarker-based cancer detection tests.
Collapse
Affiliation(s)
- Maria Luísa S. Silva
- Unidade de Aprendizagem ao Longo da Vida, Universidade Aberta, 1269-001 Lisboa, Portugal
| |
Collapse
|
3
|
Han Q, Wang X, Ding X, Hao J, Li Q, Wang J, Yu H, Tang Z, Yang F, Cai G, Zhang D, Zhu H. Salivary Glycopatterns as Potential Non-Invasive Biomarkers for Diagnosing and Reflecting Severity and Prognosis of Diabetic Nephropathy. Front Endocrinol (Lausanne) 2022; 13:790586. [PMID: 35432212 PMCID: PMC9009518 DOI: 10.3389/fendo.2022.790586] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/07/2021] [Accepted: 02/10/2022] [Indexed: 12/29/2022] Open
Abstract
Discriminating between diabetic nephropathy (DN) and non-diabetic renal disease (NDRD) can help provide more specific treatments. However, there are no ideal biomarkers for their differentiation. Thus, the aim of this study was to identify biomarkers for diagnosing and predicting the progression of DN by investigating different salivary glycopatterns. Lectin microarrays were used to screen different glycopatterns in patients with DN or NDRD. The results were validated by lectin blotting. Logistic regression and artificial neural network analyses were used to construct diagnostic models and were validated in in another cohort. Pearson's correlation analysis, Cox regression, and Kaplan-Meier survival curves were used to analyse the correlation between lectins, and disease severity and progression. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) and bioinformatics analyses were used to identify corresponding glycoproteins and predict their function. Both the logistic regression model and the artificial neural network model achieved high diagnostic accuracy. The levels of Aleuria aurantia lectin (AAL), Lycopersicon esculentum lectin (LEL), Lens culinaris lectin (LCA), Vicia villosa lectin (VVA), and Narcissus pseudonarcissus lectin (NPA) were significantly correlated with the clinical and pathological parameters related to DN severity. A high level of LCA and a low level of LEL were associated with a higher risk of progression to end-stage renal disease. Glycopatterns in the saliva could be a non-invasive tool for distinguishing between DN and NDRD. The AAL, LEL, LCA, VVA, and NPA levels could reflect the severity of DN, and the LEL and LCA levels could indicate the prognosis of DN.
Collapse
Affiliation(s)
- Qiuxia Han
- Department of Nephrology, The First Medical Centre, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center of Kidney Diseases, Beijing Key Laboratory of Kidney Disease, Beijing, China
- School of Medicine, Nankai University, Tianjin, China
| | - Xiaochen Wang
- Department of Nephrology, The First Medical Centre, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center of Kidney Diseases, Beijing Key Laboratory of Kidney Disease, Beijing, China
| | - Xiaonan Ding
- Department of Nephrology, The First Medical Centre, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center of Kidney Diseases, Beijing Key Laboratory of Kidney Disease, Beijing, China
| | - Jing Hao
- Department of Nephrology, The First Medical Centre, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center of Kidney Diseases, Beijing Key Laboratory of Kidney Disease, Beijing, China
| | - Qi Li
- Department of Nephrology, The First Medical Centre, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center of Kidney Diseases, Beijing Key Laboratory of Kidney Disease, Beijing, China
| | - Jifeng Wang
- The Key Laboratory of Protein and Peptide Pharmaceuticals, Laboratory of Proteomics, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
| | - Hanjie Yu
- Laboratory for Functional Glycomics, College of Life Sciences, Northwest University, Xi’an, China
| | - Zhen Tang
- Laboratory for Functional Glycomics, College of Life Sciences, Northwest University, Xi’an, China
| | - Fuquan Yang
- The Key Laboratory of Protein and Peptide Pharmaceuticals, Laboratory of Proteomics, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
| | - Guangyan Cai
- Department of Nephrology, The First Medical Centre, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center of Kidney Diseases, Beijing Key Laboratory of Kidney Disease, Beijing, China
- School of Medicine, Nankai University, Tianjin, China
| | - Dong Zhang
- Department of Nephrology, The First Medical Centre, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center of Kidney Diseases, Beijing Key Laboratory of Kidney Disease, Beijing, China
| | - Hanyu Zhu
- Department of Nephrology, The First Medical Centre, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center of Kidney Diseases, Beijing Key Laboratory of Kidney Disease, Beijing, China
| |
Collapse
|
4
|
Baralić M, Gligorijević N, Brković V, Katrlík J, Pažitná L, Šunderić M, Miljuš G, Penezić A, Dobrijević Z, Laušević M, Nedić O, Robajac D. Fibrinogen Fucosylation as a Prognostic Marker of End-Stage Renal Disease in Patients on Peritoneal Dialysis. Biomolecules 2020; 10:E1165. [PMID: 32784866 PMCID: PMC7466146 DOI: 10.3390/biom10081165] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2020] [Revised: 08/01/2020] [Accepted: 08/06/2020] [Indexed: 12/22/2022] Open
Abstract
Glycosylation may strongly affect protein structure and functions. A high risk of cardiovascular complications seen in patients with end-stage renal disease (ESRD) is, at least partly associated with delayed clot formation, increased clot strength, and delayed cloth lysis. Taking into consideration that fibrinogen mediates these processes, we isolated fibrinogen from the plasma from patients with ESRD on peritoneal dialysis (ESRD-PD), and examined glycosylation of native fibrinogen and its subunits by lectin-based microarray and lectin blotting. Compared to healthy controls, fibrinogen from patients had increased levels of A2BG2 and decreased levels of FA2 glycan. The distribution of glycans on individual chains was also affected, with the γ chain, responsible for physiological functions of fibrinogen (such as coagulation and platelet aggregation), being most prone to these alterations. Increased levels of multi-antennary N-glycans in ESRD-PD patients were also associated with the type of dialysis solutions, whereas an increase in the fucosylation levels was strongly related to the peritoneal membrane damage. Consequently, investigation of fibrinogen glycans can offer better insight into fibrinogen-related complications observed in ESRD-PD patients and, additionally, contribute to prognosis, choice of personalised therapy, determination of peritoneal membrane damage, and the length of utilization of peritoneum for dialysis.
Collapse
Affiliation(s)
- Marko Baralić
- Department of Nephrology, Clinical Centre of Serbia, 11000 Belgrade, Serbia; (M.B.); (V.B.); (M.L.)
| | - Nikola Gligorijević
- Department of Metabolism, Institute for the Application of Nuclear Energy (INEP), University of Belgrade, 11080 Belgrade, Serbia; (N.G.); (M.Š.); (G.M.); (A.P.); (Z.D.); (O.N.)
| | - Voin Brković
- Department of Nephrology, Clinical Centre of Serbia, 11000 Belgrade, Serbia; (M.B.); (V.B.); (M.L.)
- School of Medicine, University of Belgrade, 11000 Belgrade, Serbia
| | - Jaroslav Katrlík
- Institute of Chemistry, Slovak Academy of Sciences, 84538 Bratislava, Slovakia; (J.K.); (L.P.)
| | - Lucia Pažitná
- Institute of Chemistry, Slovak Academy of Sciences, 84538 Bratislava, Slovakia; (J.K.); (L.P.)
| | - Miloš Šunderić
- Department of Metabolism, Institute for the Application of Nuclear Energy (INEP), University of Belgrade, 11080 Belgrade, Serbia; (N.G.); (M.Š.); (G.M.); (A.P.); (Z.D.); (O.N.)
| | - Goran Miljuš
- Department of Metabolism, Institute for the Application of Nuclear Energy (INEP), University of Belgrade, 11080 Belgrade, Serbia; (N.G.); (M.Š.); (G.M.); (A.P.); (Z.D.); (O.N.)
| | - Ana Penezić
- Department of Metabolism, Institute for the Application of Nuclear Energy (INEP), University of Belgrade, 11080 Belgrade, Serbia; (N.G.); (M.Š.); (G.M.); (A.P.); (Z.D.); (O.N.)
| | - Zorana Dobrijević
- Department of Metabolism, Institute for the Application of Nuclear Energy (INEP), University of Belgrade, 11080 Belgrade, Serbia; (N.G.); (M.Š.); (G.M.); (A.P.); (Z.D.); (O.N.)
| | - Mirjana Laušević
- Department of Nephrology, Clinical Centre of Serbia, 11000 Belgrade, Serbia; (M.B.); (V.B.); (M.L.)
- School of Medicine, University of Belgrade, 11000 Belgrade, Serbia
| | - Olgica Nedić
- Department of Metabolism, Institute for the Application of Nuclear Energy (INEP), University of Belgrade, 11080 Belgrade, Serbia; (N.G.); (M.Š.); (G.M.); (A.P.); (Z.D.); (O.N.)
| | - Dragana Robajac
- Department of Metabolism, Institute for the Application of Nuclear Energy (INEP), University of Belgrade, 11080 Belgrade, Serbia; (N.G.); (M.Š.); (G.M.); (A.P.); (Z.D.); (O.N.)
| |
Collapse
|
5
|
Kitakaze K, Taniuchi S, Kawano E, Hamada Y, Miyake M, Oyadomari M, Kojima H, Kosako H, Kuribara T, Yoshida S, Hosoya T, Oyadomari S. Cell-based HTS identifies a chemical chaperone for preventing ER protein aggregation and proteotoxicity. eLife 2019; 8:e43302. [PMID: 31843052 PMCID: PMC6922633 DOI: 10.7554/elife.43302] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2018] [Accepted: 11/24/2019] [Indexed: 02/06/2023] Open
Abstract
The endoplasmic reticulum (ER) is responsible for folding secretory and membrane proteins, but disturbed ER proteostasis may lead to protein aggregation and subsequent cellular and clinical pathologies. Chemical chaperones have recently emerged as a potential therapeutic approach for ER stress-related diseases. Here, we identified 2-phenylimidazo[2,1-b]benzothiazole derivatives (IBTs) as chemical chaperones in a cell-based high-throughput screen. Biochemical and chemical biology approaches revealed that IBT21 directly binds to unfolded or misfolded proteins and inhibits protein aggregation. Finally, IBT21 prevented cell death caused by chemically induced ER stress and by a proteotoxin, an aggression-prone prion protein. Taken together, our data show the promise of IBTs as potent chemical chaperones that can ameliorate diseases resulting from protein aggregation under ER stress.
Collapse
Affiliation(s)
- Keisuke Kitakaze
- Division of Molecular Biology, Institute for Genome Research, Institute of Advanced Medical SciencesTokushima UniversityTokushimaJapan
- Fujii Memorial Institute of Medical Sciences, Institute of Advanced Medical SciencesTokushima UniversityTokushimaJapan
- Department of PharmacologyKawasaki Medical SchoolKurashikiJapan
| | - Shusuke Taniuchi
- Division of Molecular Biology, Institute for Genome Research, Institute of Advanced Medical SciencesTokushima UniversityTokushimaJapan
- Fujii Memorial Institute of Medical Sciences, Institute of Advanced Medical SciencesTokushima UniversityTokushimaJapan
- Department of Molecular Research, Diabetes Therapeutics and Research Center, Institute of Advanced Medical SciencesTokushima UniversityTokushimaJapan
| | - Eri Kawano
- Division of Molecular Biology, Institute for Genome Research, Institute of Advanced Medical SciencesTokushima UniversityTokushimaJapan
| | - Yoshimasa Hamada
- Division of Molecular Biology, Institute for Genome Research, Institute of Advanced Medical SciencesTokushima UniversityTokushimaJapan
- Fujii Memorial Institute of Medical Sciences, Institute of Advanced Medical SciencesTokushima UniversityTokushimaJapan
| | - Masato Miyake
- Division of Molecular Biology, Institute for Genome Research, Institute of Advanced Medical SciencesTokushima UniversityTokushimaJapan
- Fujii Memorial Institute of Medical Sciences, Institute of Advanced Medical SciencesTokushima UniversityTokushimaJapan
- Department of Molecular Research, Diabetes Therapeutics and Research Center, Institute of Advanced Medical SciencesTokushima UniversityTokushimaJapan
| | - Miho Oyadomari
- Division of Molecular Biology, Institute for Genome Research, Institute of Advanced Medical SciencesTokushima UniversityTokushimaJapan
| | - Hirotatsu Kojima
- Drug Discovery Initiative (DDI)The University of TokyoTokyoJapan
| | - Hidetaka Kosako
- Fujii Memorial Institute of Medical Sciences, Institute of Advanced Medical SciencesTokushima UniversityTokushimaJapan
| | - Tomoko Kuribara
- Laboratory of Chemical Bioscience, Institute of Biomaterials and BioengineeringTokyo Medical and Dental University (TMDU)TokyoJapan
| | - Suguru Yoshida
- Laboratory of Chemical Bioscience, Institute of Biomaterials and BioengineeringTokyo Medical and Dental University (TMDU)TokyoJapan
| | - Takamitsu Hosoya
- Laboratory of Chemical Bioscience, Institute of Biomaterials and BioengineeringTokyo Medical and Dental University (TMDU)TokyoJapan
| | - Seiichi Oyadomari
- Division of Molecular Biology, Institute for Genome Research, Institute of Advanced Medical SciencesTokushima UniversityTokushimaJapan
- Fujii Memorial Institute of Medical Sciences, Institute of Advanced Medical SciencesTokushima UniversityTokushimaJapan
- Department of Molecular Research, Diabetes Therapeutics and Research Center, Institute of Advanced Medical SciencesTokushima UniversityTokushimaJapan
| |
Collapse
|